Fierce Biotech

Novartis inks $3.2B subcutaneous drug delivery deal with Alteogen

Novartis has struck a deal worth up to $3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and ...
Fierce Biotech

Teva autoimmune antibody notches ph. 2 win in celiac disease

Teva Pharmaceutical's dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s ...
Fierce Biotech

SEC, FDA sign info-sharing agreement as a ‘signal to the market’ on insider trading

The SEC and the FDA have signed a three-year agreement to step up cooperation and information-sharing capabilities aiming to ...
Fierce Biotech

TScan axes 75% of workforce to make room for solid tumor programs

TScan Therapeutics will reduce its workforce by 75% following the pause of its hematological and autoimmune programs. | TCR-T ...
Fierce Biotech

Fortrea boosts early-phase CRO platform with $45M acquisition of Worldwide division

Fortrea has agreed to acquire the early-phase services division of fellow CRO Worldwide Clinical Trials for $45 million. | Fortrea has agreed to acquire the early-phase services division of fellow CRO ...